SCHEMBL2389641

SCHEMBL2389641

O=C(O)C(F)c1ccccc1-c1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.47
HSP90AB1 P08238 2/20 0.47
MAOB P27338 1/20 0.43
CHRM1 P11229 2/20 0.43
CHRM3 P20309 1/20 0.43
NAT1 P18440 1/20 0.42
MAP4K4 O95819 1/20 0.41
PTGS2 P35354 1/20 0.41
IDO1 P14902 1/20 0.41
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
RORB Q92753 1/20 0.40
TYMP P19971 1/20 0.40
KAT6A Q92794 1/20 0.39
CTSA P10619 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
PDK2 Q15119 1/20 0.39
PTPRC P08575 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391830 0.87 HSP90AA1 (0.45) HSP90AA1HSP90AB1MAOBCHRM1CHRM3
SCHEMBL2389486 0.84 MAOB (0.46) MAOBPTGS2KAT6AKMO
SCHEMBL2391709 0.84 KMT2A (0.47) HSP90AA1HSP90AB1CHRM3PTGS2MEN1
SCHEMBL9890685 0.82 PTGS2 (0.53) HSP90AA1HSP90AB1MAOBCHRM1CHRM3
SCHEMBL9890709 0.78 HSP90AA1 (0.46) HSP90AA1HSP90AB1CHRM1CHRM3RORB
SCHEMBL9890803 0.76 CHRM1 (0.46) HSP90AA1HSP90AB1MAOBCHRM1CHRM3
SCHEMBL9890801 0.75 CXCL8 (0.48) HSP90AA1HSP90AB1MAOBCHRM1CHRM3
SCHEMBL11830951 0.74 CHRM1 (0.46) HSP90AA1HSP90AB1CHRM1CHRM3CTSA
SCHEMBL2391431 0.74 SLC6A4 (0.45) MAOBPTGS2KMT2A
SCHEMBL2393361 0.73 MAOB (0.43) MAOBMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
WO-2010055911-A1 BIPHENYLACETAMIDE DERIVATIVE 大日本住友製薬株式会社 (JP) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HSP90AA1 1699/4885HSP90AB1 2118/4885MAOB 1411/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HSP90AA1 1699/4885HSP90AB1 2118/4885MAOB 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.